The US Food and Drug Administration won’t be conducting on-site domestic surveillance inspections for another two weeks at a minimum, the agency announced on 21 January.
The FDA decided on 29 December to halt inspections through at least 19 January because of the COVID-19 Omicron variant. But now that timeline has been lengthened. (Also see "